Towards a European personalized registry for colorectal cancer patients: 919 patients have already enrolled!

About the project Download the brochure

What's New?

Playing defensive line on a football team requires a mixture of strength, agility and speed, and each can be developed a

in Media

an attorney, saying he now disabled for life. The counterfeit jerseys are being confiscated and the vendors arrested. And Canadian anthems, since it has a team based in Toronto.. According to buyers, Fox is charging around $741,811 for each 30 second increment in its eight game juggernaut, which is replete with appearances by the NFL’s… Read more »

The targets on his other five 20 plus yard attempts: Torrey Smith (2), Alshon Jeffery (2) and Agholor. According to the

in Media

some sort of harness to counter weigh the heaviness of the protruding beak. Number two league for betting is the NBA.. Visa, Ford, Nike, Anheuser Busch InBev, Microsoft, McDonald’s, PepsiCo and Bridgestone are among the league’s top tier partners and almost all have remained silent on what was possibly the most political and polarizing Sunday… Read more »

SPECTAcolor viable next generation multinational cancer clinical trial infrastructure

in Media, Press Releases

dresden

Over 500 patients in and availability of high quality biological materials SPECTAcolor’s successful start has demonstrated its viability to facilitate next generation cancer clinical trials. womens air jordan Nike Air Max 2017 Heren blauw Nike Air Max 2016 Heren It has been successfully implemented across 21 clinical centers located in nine countries in Europe, cheap… Read more »

Ignyta and EORTC Announce Entrectinib as 1st Investigational Cancer Agent in EORTC SPECTA

in Media, Press Releases

research-2

SAN DIEGO and BRUSSELS–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, and the European Organisation for Research and Treatment of Cancer (EORTC) today announced that they will collaborate via EORTC’s Screening Patients for Efficient Clinical Trial Access (SPECTA) biomarker screening initiative to identify patients who harbor a gene rearrangement to NTRK1, NTRK3, ROS1… Read more »